Qiagen (QGEN) Projected to Post Quarterly Earnings on Wednesday

Qiagen (NYSE:QGEN) is expected to release its Q4 2025 results after the market closes on Wednesday, February 4th. Analysts expect the company to announce earnings of $0.59 per share and revenue of $528.5340 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 5, 2026 at 9:30 AM ET.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.03. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.The business had revenue of $532.58 million for the quarter, compared to the consensus estimate of $525.68 million. During the same quarter last year, the business posted $0.60 earnings per share. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. On average, analysts expect Qiagen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Qiagen Trading Down 2.7%

NYSE:QGEN opened at $52.20 on Tuesday. The firm has a market capitalization of $11.02 billion, a P/E ratio of 26.95, a P/E/G ratio of 2.56 and a beta of 0.67. The company has a fifty day moving average of $49.58 and a 200 day moving average of $49.64. The company has a quick ratio of 2.30, a current ratio of 2.60 and a debt-to-equity ratio of 0.45. Qiagen has a 52 week low of $39.61 and a 52 week high of $57.81.

Hedge Funds Weigh In On Qiagen

A number of large investors have recently bought and sold shares of the business. Amundi boosted its stake in Qiagen by 4.4% in the third quarter. Amundi now owns 4,290,273 shares of the company’s stock valued at $201,471,000 after acquiring an additional 181,509 shares in the last quarter. Boston Partners purchased a new position in shares of Qiagen in the third quarter worth about $179,450,000. Sei Investments Co. lifted its holdings in shares of Qiagen by 5.0% during the third quarter. Sei Investments Co. now owns 1,902,296 shares of the company’s stock worth $84,995,000 after purchasing an additional 90,294 shares during the period. Dimensional Fund Advisors LP acquired a new stake in shares of Qiagen during the third quarter worth about $58,079,000. Finally, Invesco Ltd. increased its holdings in Qiagen by 29.1% in the 3rd quarter. Invesco Ltd. now owns 1,298,776 shares of the company’s stock worth $58,029,000 after buying an additional 292,751 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. UBS Group restated a “neutral” rating on shares of Qiagen in a report on Wednesday, January 21st. Wall Street Zen lowered shares of Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, January 10th. Barclays restated an “overweight” rating and issued a $57.89 price target (up previously from $55.79) on shares of Qiagen in a research report on Monday, December 15th. Deutsche Bank Aktiengesellschaft lowered shares of Qiagen from a “buy” rating to a “hold” rating and increased their price objective for the company from $52.00 to $54.00 in a research report on Thursday, January 22nd. Finally, Citigroup downgraded shares of Qiagen from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $57.89 to $52.63 in a report on Thursday, December 11th. Two investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, Qiagen presently has an average rating of “Hold” and an average price target of $53.04.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.